Trial
NCT01399593
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Antibody Mediated Rejection
Intervention
Eculizumab
Why stopped
Did not achieve statistical significance for primary endpoint
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-10-03